Alopecia Areata — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.
Zhan Jinshan et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41918293/
- 2.
Early Initiation of UVB Phototherapy May Improve Outcomes in Alopecia Areata.
Yamamoto Aya et al. — Photodermatology, photoimmunology & photomedicine (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41928620/
- 3.
Associations of Lichen Sclerosus With Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Lai Chien-Cheng et al. — BJOG : an international journal of obstetrics and gynaecology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41725174/
- 4.
Cedrol from Platycladus orientalis (L.) Franco regulates M1/M2 polarization of macrophages and promotes hair regeneration.
Li Tao et al. — Journal of ethnopharmacology (24 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41611183/
- 5.
Racial and Ethnic Representation in Clinical Trials of Janus Kinase Inhibitors for Dermatologic Conditions: A Systematic Review.
Olagun-Samuel Christine et al. — Journal of drugs in dermatology : JDD (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41931696/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT05723198
- 2.
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Recruiting — Phase 1 — Dren Bio
https://clinicaltrials.gov/study/NCT06602232
- 3.
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Recruiting — Phase 2 — AbbVie
https://clinicaltrials.gov/study/NCT07155187
- 4.
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Recruiting — Phase 1 — Forte Biosciences, Inc.
https://clinicaltrials.gov/study/NCT07205159
- 5.
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
Recruiting — Phase 1 — Olix Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT07327359
- 6.
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT06012240
- 7.
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
Recruiting — Phase 3 — Samson Clinical Operations Pty Ltd
https://clinicaltrials.gov/study/NCT06924632
- 8.
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia
Recruiting — Phase 1 — Absci Pty Ltd.
https://clinicaltrials.gov/study/NCT07317544
- 9.
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Recruiting — Phase 2 — AbbVie
https://clinicaltrials.gov/study/NCT07005102
- 10.
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Recruiting — Phase 3 — Pfizer
https://clinicaltrials.gov/study/NCT06163326
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Alopecia Areata
Alopecia areata is an autoimmune condition that causes unpredictable hair loss, ranging from small patches to complete loss of scalp or body hair. It can affect people of any age. Recent years have seen significant research advances, including new JAK inhibitor treatments now approved in several countries.
Most Recent Research
UNLABELLED: To characterize and compare the post-marketing safety profiles of Janus kinase (JAK) inhibitors used in alopecia areata (AA), including tofacitinib, baricitinib, ruxolitinib, and ritlecitinib. METHODS: Reports associated with JAK inhibitors in AA (2015-2025) were retrieved from the FDA Adverse Event Reporting System (FAERS). Disproportionality analyses utilized within-class and external non-JAK comparisons. Additionally, time-to-onset (TTO), serious adverse event (SAE) profiles, and sensitivity analyses were assessed. RESULTS: Among 1,905 identified reports (baricitinib [n = 881], ritlecitinib [n = 515], tofacitinib [n = 489], ruxolitinib [n = 20]), safety signals varied across agents. Tofacitinib showed signals involving neuropsychiatric and autoimmune events; baricitinib was associated with thrombocytosis, deep vein thrombosis, and breast cancer; ruxolitinib with pyrexia and elevated blood cholesterol; and ritlecitinib with gastrointestinal events and creatine phosphokinase elevation. TTO patterns were also heterogeneous, with earlier onset for tofacitinib and ruxolitinib, clustering within the first month for ritlecitinib, and a relatively delayed onset for baricitinib. Across the class, serious outcomes were most commonly related to infections, although the distribution of clinical outcomes differed by agent. CONCLUSIONS: JAK inhibitors used in AA demonstrated heterogeneous post-marketing safety patterns not fully captured by class-level warnings. These findings support agent-specific surveillance and individualized risk assessment in clinical practice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.